Neurocrine Biosciences, Inc. NBIX

NAS: NBIX | ISIN: US64125C1099   2/10/2026
143,18 USD (+1,76%)
(+1,76%)   2/10/2026
Grafiek Neurocrine Biosciences, Inc. Grafiek Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. in het nieuws

30 september 2026 · Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference · Persbericht

28 september 2026 · Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer · Persbericht

2 september 2026 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in September · Persbericht

12 augustus 2026 · Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia · Persbericht

7 augustus 2026 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist · Persbericht

30 juli 2026 · Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results · Persbericht

23 juli 2026 · Neurocrine Biosciences Announces Key Leadership Hiring, Promotions · Persbericht

21 juli 2026 · Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer · Persbericht

9 juli 2026 · Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results · Persbericht

1 juli 2026 · Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia · Persbericht

Profiel Neurocrine Biosciences, Inc.

Biotechnologie
Gezondheidstechnologie
Productie
Productie van biologische producten

Website: www.neurocrine.com

Hoofdzetel: San Diego, California vlag Verenigde Staten

Mijn selecties